Robert W. Baird analyst Michael Polark maintained a Buy rating on Inspire Medical Systems (NYSE:INSP) on Friday, setting a price target of $260, which is approximately 52.06% above the present share price of $170.98.
Polark expects Inspire Medical Systems to post earnings per share (EPS) of -$0.60 for the second quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in Inspire Medical Systems, with an average price target of $260.25.
The analysts price targets range from a high of $266 to a low of $255.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $40.35 million and a net profit of -$15.69 million. The company's market cap is $4.65 billion.
According to TipRanks.com, Robert W. Baird analyst Michael Polark is currently ranked with 2 stars on a 0-5 stars ranking scale, with an average return of 3.9% and a 44.19% success rate.
Inspire Medical Systems, Inc. engages in the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea. It offers inspire therapy, which consists of a remote control and implantable components that includes pressure sensing lead, a neurostimulator, and a stimulation lead. The company was founded by Timothy P. Herbert in November 2007 and is headquartered in Golden Valley, MN.